IndieBio

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, that focuses on enhancing maternal health outcomes. Founded in 2019, the company has developed a home-based early detection test specifically aimed at identifying preeclampsia, a potentially severe pregnancy complication. Their product includes a low-cost and reliable detection strip that allows mothers to self-screen for preeclampsia periodically. This innovation is designed to improve accessibility to early diagnosis, enabling women to seek timely medical care and mitigate the risks associated with this condition. Kalia Health's commitment to safe and affordable maternal health solutions positions it as a valuable contributor to improving health outcomes for expectant mothers.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, that focuses on enhancing maternal health outcomes. Founded in 2019, the company has developed a home-based early detection test specifically aimed at identifying preeclampsia, a potentially severe pregnancy complication. Their product includes a low-cost and reliable detection strip that allows mothers to self-screen for preeclampsia periodically. This innovation is designed to improve accessibility to early diagnosis, enabling women to seek timely medical care and mitigate the risks associated with this condition. Kalia Health's commitment to safe and affordable maternal health solutions positions it as a valuable contributor to improving health outcomes for expectant mothers.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

JointechLabs, Inc. is a company that specializes in point-of-care regenerative medicine therapies, headquartered in Brandon, Florida. The organization develops innovative medical devices, including the MiniTC® for the United States and the Mini-Stem System® for international markets. These devices facilitate the processing of autologous body fat, enabling safe and efficient use in non-surgical orthopedic and aesthetic procedures within medical offices. By providing a closed-loop disposable system for human tissue processing, JointechLabs simplifies the creation of high-quality injectable fat grafts and fat-derived stem cells, making individualized cell and tissue-based therapies more accessible and cost-effective for hospitals and clinics. Additionally, the company is expanding its product pipeline to include biologic drugs and 3D bioprinted products aimed at orthopedic, wound healing, and plastic and reconstructive surgery applications.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Clinicai Inc. is a technology company that specializes in health monitoring through innovative bathroom diagnostics. Established in 2016 and located in San Francisco, California, Clinicai develops smart toilet monitoring devices equipped with sensor networks and artificial intelligence. These devices are designed to non-invasively track health by analyzing stool and urine, facilitating early detection of gastrointestinal cancers and other diseases. By creating a connected ecosystem of monitoring platforms and embedded health tracking sensors, Clinicai enables individuals to gather important health data within the home environment, allowing for proactive management of potential health risks.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Mouth2Mouth is a healthcare startup that develops personalized probiotics for oral health. Based on microbiome data from thousands of healthy individuals, their AI-driven platform determines consortia of beneficial bacteria that fight widespread conditions such as tooth decay, gum disease, and bad breath. The company is on a mission to improve oral hygiene and provide a solution to oral diseases by use of an all-natural process.

JointechLabs, Inc. is a company that specializes in point-of-care regenerative medicine therapies, headquartered in Brandon, Florida. The organization develops innovative medical devices, including the MiniTC® for the United States and the Mini-Stem System® for international markets. These devices facilitate the processing of autologous body fat, enabling safe and efficient use in non-surgical orthopedic and aesthetic procedures within medical offices. By providing a closed-loop disposable system for human tissue processing, JointechLabs simplifies the creation of high-quality injectable fat grafts and fat-derived stem cells, making individualized cell and tissue-based therapies more accessible and cost-effective for hospitals and clinics. Additionally, the company is expanding its product pipeline to include biologic drugs and 3D bioprinted products aimed at orthopedic, wound healing, and plastic and reconstructive surgery applications.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

MezoMax, Inc. is a biotechnology company based in San Francisco, California, founded in 2017. It specializes in developing oral therapies for nonhealing fractures and bone-related diseases, focusing on enhancing fracture healing and treating osteoporosis, particularly in elderly patients. The company’s innovative product features a novel calcium gluconate stereoisomer that regulates calcium and mineral metabolism, facilitating faster osteogenesis. By stimulating bone-forming cells, MezoMax's small molecule drug offers a safer and more effective approach to bone repair, enabling healthcare professionals to improve patient outcomes in the management of fractures and rare bone diseases.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Nuro Corp, founded in 2017 and based in Waterloo, Canada, specializes in developing neurologically-powered communication software designed to assist doctors and patients. The company offers a range of products under its Neural Operating System (NUOS), which enables instant communication and computing through brain signals, eliminating the need for invasive procedures. Key offerings include NUOS ALS for ALS patients, NUOS TRAUMA for individuals with tetraplegia, and NUOS STROKE for stroke victims. Additionally, NUOS AI provides immediate access to insights derived from neurological and behavioral data, facilitating enhanced communication for incapacitated patients in various healthcare settings, including post-surgery, intensive care units, nursing homes, and rehabilitation facilities.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative treatments for incurable cancers and neurodegenerative diseases. Founded in 2017 and based in San Diego, California, the company utilizes a machine vision and learning platform to drive diseased stem cells toward non-diseased states. Its proprietary technology, known as microscopic imaging of epigenetic landscapes (MIEL), facilitates the discovery of small molecules that can induce epigenetic changes, allowing for the differentiation or reversal of cancerous cells into benign types, which holds potential for curative outcomes. Additionally, Stelvio is pursuing a personalized approach to glioblastoma treatment, leveraging its team's expertise in scientific innovation and clinical management to advance novel drug therapies and precision medicine diagnostics.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

Qidni Labs Inc., based in Kitchener, Canada, is a medical device company focused on developing innovative renal replacement therapies. The company is creating a portable dialysis technology that is nearly waterless and can be fully powered by rechargeable batteries. This design aims to simplify the infrastructure required for traditional dialysis, making treatment more accessible for kidney failure patients worldwide. Qidni Labs' system facilitates the removal of uremic toxins and other solutes from large volumes of whole blood, supporting patients in leading better lives. Additionally, the technology incorporates cloud-based remote monitoring to enhance treatment management, thereby addressing barriers to accessing dialysis care.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

AstRoNA Biotechnologies Inc., established in 2015 and based in Davis, California, focuses on developing and manufacturing handheld devices for detecting food contamination. The company addresses the critical issue of food safety, as food poisoning affects over one in six individuals in the United States annually, leading to more than 128,000 hospitalizations. AstRoNA's innovative technology allows for on-site screening of all food types, significantly reducing the time required for testing from the current standard of 48 hours to under one hour. This capability enables users in the food production sector to quickly identify contaminants, enhancing safety throughout the entire food supply chain, from production to consumption.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

V-Sense Medical specializes in the development of remote medical monitoring devices that utilize advanced radar technology to monitor vital signs without direct contact with patients. By eliminating the need for traditional instruments such as wires, electrodes, and blood pressure cuffs, V-Sense Medical addresses significant challenges in medical facilities, including patient safety and comfort, measurement accuracy, and the efficiency of healthcare delivery. Their innovative approach allows for continuous monitoring of critical health metrics like heart rate and respiratory rate, providing healthcare professionals with real-time insights and alerts regarding patient health. This technology not only enhances the precision of medical assessments but also streamlines workflows, ultimately facilitating quicker and more effective patient care in urgent medical environments.

MYI Diagnostics is a biomedical research company based in San Diego, California, founded in 2015 by Nicholas J. Schork, Devon Cayer, and Kristopher L. Nazor. The company specializes in multiplexed proteomic profiling, focusing on the development of single-cell quantification technology and multiplexed immunocytochemical analytical platforms. These innovations are designed to analyze patient biopsies and identify unique biomarkers associated with various diseases, including cancers, infectious diseases, and metabolic conditions. By replacing numerous targeted diagnostics with their advanced methodologies, MYI Diagnostics aims to provide healthcare providers with actionable, individualized information that can enhance clinical intervention strategies.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.